165735-95-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-METHYL-2-PHENYL-1,3-THIAZOL-5-YL)METHANAMINE is used as a building block for the preparation of pharmaceuticals and other biologically active molecules. It plays a crucial role in the development of new drugs for the treatment of various diseases.
Used in Organic Synthesis:
(4-METHYL-2-PHENYL-1,3-THIAZOL-5-YL)METHANAMINE is used as a key intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used in Medicinal Chemistry:
(4-METHYL-2-PHENYL-1,3-THIAZOL-5-YL)METHANAMINE is used in medicinal chemistry for the design and synthesis of novel therapeutic agents, contributing to advancements in drug discovery and development.

InChI:InChI=1/C11H12N2S/c1-8-10(7-12)14-11(13-8)9-5-3-2-4-6-9/h2-6H,7,12H2,1H3

Upstream product

• 55327-23-6 4-methyl-2-phenylthiazole-5-carbaldehyde 
• 2227-79-4 benzenecarbothioamide 
• 181424-15-7 5-(bromomethyl)-4-methyl-2-[4-phenyl]-1,3-thiazole 
• 61291-91-6 (4-methyl-2-phenyl-1,3-thiazol-5-yl) methanol 
• 111559-41-2 (4-Methyl-2-phenyl-5-thiazolyl)essigsaeure-ethylester 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents

Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future.